scPharmaceuticals
scPharmaceuticals is a patient-centric, innovative pharmaceutical company focused on revolutionizing cardiorenal care through integrated treatments. They develop accessible healthcare solutions aimed at improving health outcomes and quality of life, leveraging commercial expertise, industry relationships, and a specialty care model to address unmet patient needs in cardiovascular and renal conditions.
Industries
Nr. of Employees
small (1-50)
scPharmaceuticals
25 Mall Road, Suite 203, Burlington, MA 01803
Patents
Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US-12048709-B2
View DetailsConcentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US-11998555-B2
View Details
Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US-12048709-B2
View DetailsConcentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US-11998555-B2
View DetailsProducts
FUROSCIX (furosemide injection) 80 mg/10 mL for subcutaneous use
A concentrated subcutaneous furosemide injectable formulation indicated to treat edema (fluid overload) in adults with chronic heart failure or chronic kidney disease; designed to support outpatient fluid management.
FUROSCIX (furosemide injection) 80 mg/10 mL for subcutaneous use
A concentrated subcutaneous furosemide injectable formulation indicated to treat edema (fluid overload) in adults with chronic heart failure or chronic kidney disease; designed to support outpatient fluid management.
Services
End-to-end commercialization services for late-stage cardiovascular and renal therapeutic and diagnostic products, including market analysis, brand and medical affairs planning, distribution strategy, payer engagement and post-launch support.
Support for regulatory dossier preparation, interactions with regulatory agencies, supplemental submissions and medical affairs activities to support approvals and indication expansions.
Operational execution of commercial launches with specialty distribution, targeted pharmacy navigation, and patient access programs to support outpatient treatment adoption.
End-to-end commercialization services for late-stage cardiovascular and renal therapeutic and diagnostic products, including market analysis, brand and medical affairs planning, distribution strategy, payer engagement and post-launch support.
Support for regulatory dossier preparation, interactions with regulatory agencies, supplemental submissions and medical affairs activities to support approvals and indication expansions.
Operational execution of commercial launches with specialty distribution, targeted pharmacy navigation, and patient access programs to support outpatient treatment adoption.
Expertise Areas
- Clinical trial management
- Drug-device combination development
- Subcutaneous injectable development
- Commercialization and market access
Key Technologies
- On-body infusor and autoinjector delivery systems
- High-concentration subcutaneous injectable formulations
- Drug-device combination platforms
- Phase 2/3 and PK clinical study execution
News & Updates
Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025. Fully launched FUROSCIX in the second approved indication, Chronic Kidney Disease, in April 2025. Autoinjector on track for sNDA submission in Q3 2025.
Management to host conference call and webcast after-market on May 14, 2025.
Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025. Fully launched FUROSCIX in the second approved indication, Chronic Kidney Disease, in April 2025. Autoinjector on track for sNDA submission in Q3 2025.
Management to host conference call and webcast after-market on May 14, 2025.